Special Issue "Adjuvants for Human Vaccines"
Deadline for manuscript submissions: 30 April 2023 | Viewed by 178
Interests: vaccine; drug delivery; formulation development
Interests: vaccine delivery; microneedle based vaccine delivery; vaccine delivery using oral dissolving films
Special Issues, Collections and Topics in MDPI journals
The journal Pharmaceuticals is planning to publish a Special Issue covering the topic “Adjuvants for Human Vaccines”, and we are inviting you to contribute an article to this volume.
The current COVID-19 pandemic has revealed the urgency of vaccines for global health. Vaccines are the most effective method to prevent infectious diseases. In recent decades, mass vaccination has dramatically reduced the incidence of many life-threatening diseases. The vaccine development process involves antigen identification, development and expression, and finally formulation development. Most vaccine formulations contain an antigenic component that mimics the pathogen to trigger immunity, and an adjuvant component that amplifies the quality and quantity of the immune response to the antigen. There are several ways adjuvants act to enhance the immunogenicity of vaccines. For example, adjuvants act as a depot for the sustained release of the antigen at the site of administration, initiate the up-regulation of cytokines and chemokines, arrange cellular recruitment at the site of injection, increase antigen uptake and presentation to antigen-presenting cells (APC) and/or cause the activation of inflammasomes. Although commonly used with human vaccines to increase efficiency, not many adjuvants have been developed thus far. Only a few adjuvants have been approved by regulatory agencies to be used as vaccine components in the US. This Special Issue focuses on the emerging concepts in the development of adjuvant platforms that have the potential to be safe and to increase vaccine efficiency to protect against current and future infectious threats. Original research, review articles and short communications related to recent advances in adjuvant research for human vaccines will be welcomed.
Dr. Monzurul Roni
Dr. Mohammad N. Uddin
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune response
- vaccine development
- antigen presentation